Connection

GUILLERMINA LOZANO to Proto-Oncogene Proteins c-mdm2

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Proto-Oncogene Proteins c-mdm2.
  1. Alterations of the Mdm2 C-Terminus Differentially Impact Its Function In Vivo. Cancer Res. 2022 04 01; 82(7):1313-1320.
    View in: PubMed
    Score: 0.625
  2. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene. 2018 01 18; 37(3):332-340.
    View in: PubMed
    Score: 0.456
  3. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene. 2016 Jan 21; 35(3):358-65.
    View in: PubMed
    Score: 0.386
  4. Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol. 2014 Aug; 233(4):380-91.
    View in: PubMed
    Score: 0.364
  5. Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget. 2014 Mar 15; 5(5):1149-56.
    View in: PubMed
    Score: 0.358
  6. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat. 2014 Jun; 35(6):728-37.
    View in: PubMed
    Score: 0.357
  7. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res. 2014 Jun; 12(6):901-11.
    View in: PubMed
    Score: 0.357
  8. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res. 2013 Jan 01; 19(1):34-41.
    View in: PubMed
    Score: 0.328
  9. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell. 2010 Nov 05; 7(5):606-17.
    View in: PubMed
    Score: 0.283
  10. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 2010 Jan; 17(1):93-102.
    View in: PubMed
    Score: 0.267
  11. p53 and MDM2: antagonists or partners in crime? Cancer Cell. 2009 Mar 03; 15(3):161-2.
    View in: PubMed
    Score: 0.252
  12. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res. 2008 Jun; 6(6):947-54.
    View in: PubMed
    Score: 0.240
  13. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008 May 15; 22(10):1337-44.
    View in: PubMed
    Score: 0.239
  14. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol. 2007 Dec; 213(4):360-8.
    View in: PubMed
    Score: 0.231
  15. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol. 2007 Aug; 27(15):5479-85.
    View in: PubMed
    Score: 0.223
  16. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 2006 Oct 01; 66(19):9502-8.
    View in: PubMed
    Score: 0.213
  17. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006 Jun; 13(6):927-34.
    View in: PubMed
    Score: 0.209
  18. Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol. 2006 Jun; 16(3):225-34.
    View in: PubMed
    Score: 0.206
  19. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3226-31.
    View in: PubMed
    Score: 0.205
  20. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol. 2006 Jan; 26(1):192-8.
    View in: PubMed
    Score: 0.203
  21. p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proc Natl Acad Sci U S A. 2020 09 22; 117(38):23663-23673.
    View in: PubMed
    Score: 0.140
  22. Daxx Functions Are p53-Independent In Vivo. Mol Cancer Res. 2018 10; 16(10):1523-1529.
    View in: PubMed
    Score: 0.120
  23. The Enigma of p53. Cold Spring Harb Symp Quant Biol. 2016; 81:37-40.
    View in: PubMed
    Score: 0.108
  24. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harb Perspect Med. 2016 08 01; 6(8).
    View in: PubMed
    Score: 0.105
  25. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene. 2016 11 03; 35(44):5713-5721.
    View in: PubMed
    Score: 0.103
  26. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Mol Cell. 2016 Jan 07; 61(1):68-83.
    View in: PubMed
    Score: 0.101
  27. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev. 2014 Aug 15; 28(16):1739-51.
    View in: PubMed
    Score: 0.092
  28. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol. 2014 Jun; 15(6):562-70.
    View in: PubMed
    Score: 0.090
  29. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev. 2013 Sep 01; 27(17):1857-67.
    View in: PubMed
    Score: 0.086
  30. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death Differ. 2012 Aug; 19(8):1381-9.
    View in: PubMed
    Score: 0.078
  31. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011 Dec 01; 71(23):7168-75.
    View in: PubMed
    Score: 0.076
  32. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle. 2011 Oct 01; 10(19):3257-62.
    View in: PubMed
    Score: 0.075
  33. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A. 2011 Jul 19; 108(29):11995-2000.
    View in: PubMed
    Score: 0.074
  34. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet. 2011 Jun; 129(6):663-73.
    View in: PubMed
    Score: 0.072
  35. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest. 2011 Mar; 121(3):851-65.
    View in: PubMed
    Score: 0.072
  36. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010 Sep 14; 18(3):220-30.
    View in: PubMed
    Score: 0.070
  37. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 2010 May 26; 5(5):e10813.
    View in: PubMed
    Score: 0.069
  38. The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ. 2008 Nov; 15(11):1772-81.
    View in: PubMed
    Score: 0.060
  39. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene. 2008 Mar 20; 27(13):1813-20.
    View in: PubMed
    Score: 0.057
  40. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007 Oct; 38(10):1553-62.
    View in: PubMed
    Score: 0.056
  41. Crippling p53 activities via knock-in mutations in mouse models. Oncogene. 2007 Apr 02; 26(15):2177-84.
    View in: PubMed
    Score: 0.055
  42. Distinct roles of Mdm2 and Mdm4 in red cell production. Blood. 2007 Mar 15; 109(6):2630-3.
    View in: PubMed
    Score: 0.054
  43. Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell. 2005 Jul; 8(1):3-4.
    View in: PubMed
    Score: 0.049
  44. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene. 2004 Oct 07; 23(46):7644-50.
    View in: PubMed
    Score: 0.046
  45. Model predictions of MDM2 mediated cell regulation. Cell Cycle. 2004 May; 3(5):655-61.
    View in: PubMed
    Score: 0.045
  46. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 2003 Dec 15; 63(24):8664-9.
    View in: PubMed
    Score: 0.044
  47. MDM2, an introduction. Mol Cancer Res. 2003 Dec; 1(14):993-1000.
    View in: PubMed
    Score: 0.044
  48. Disrupting TP53 in mouse models of human cancers. Hum Mutat. 2003 Mar; 21(3):321-6.
    View in: PubMed
    Score: 0.042
  49. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene. 2002 May 16; 21(22):3525-31.
    View in: PubMed
    Score: 0.039
  50. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis. 2002 Feb; 32(2):145-7.
    View in: PubMed
    Score: 0.039
  51. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet. 2001 Sep; 29(1):92-5.
    View in: PubMed
    Score: 0.038
  52. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 2001 Jul 05; 20(30):4041-9.
    View in: PubMed
    Score: 0.037
  53. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene. 2001 May 30; 270(1-2):277-83.
    View in: PubMed
    Score: 0.037
  54. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 2000 Mar 23; 19(13):1691-7.
    View in: PubMed
    Score: 0.034
  55. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999 Jul; 188(3):322-8.
    View in: PubMed
    Score: 0.032
  56. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 1999 Mar; 10(3):147-54.
    View in: PubMed
    Score: 0.032
  57. MDM2 function. Biochim Biophys Acta. 1998 Apr 17; 1377(2):M55-9.
    View in: PubMed
    Score: 0.030
  58. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene. 1997 Sep 25; 15(13):1527-34.
    View in: PubMed
    Score: 0.029
  59. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet. 1997 Aug; 16(4):336-7.
    View in: PubMed
    Score: 0.028
  60. Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res. 1997 Aug; 148(2):115-22.
    View in: PubMed
    Score: 0.028
  61. The organization and expression of the mdm2 gene. Genomics. 1996 May 01; 33(3):352-7.
    View in: PubMed
    Score: 0.026
  62. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995 Nov 09; 378(6553):203-6.
    View in: PubMed
    Score: 0.025
  63. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget. 2015 Jul 20; 6(20):17968-80.
    View in: PubMed
    Score: 0.025
  64. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene. 2010 Jun 03; 29(22):3287-96.
    View in: PubMed
    Score: 0.017
  65. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62.
    View in: PubMed
    Score: 0.013
  66. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol. 2005 Jun; 19(6):1646-53.
    View in: PubMed
    Score: 0.012
  67. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res. 2004 Dec 15; 64(24):9080-5.
    View in: PubMed
    Score: 0.012
  68. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
    View in: PubMed
    Score: 0.012
  69. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene. 2002 Oct 10; 21(46):7100-13.
    View in: PubMed
    Score: 0.010
  70. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem. 2002 May 31; 277(22):19251-4.
    View in: PubMed
    Score: 0.010
  71. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000 Sep 15; 14(18):2358-65.
    View in: PubMed
    Score: 0.009
  72. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999 Apr 01; 18(7):1805-14.
    View in: PubMed
    Score: 0.008
  73. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997 Mar 15; 11(6):714-25.
    View in: PubMed
    Score: 0.007
  74. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene. 1996 Oct 17; 13(8):1731-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.